BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
KRChoksey Research’s IPO Report
Tatva Chintan Pharma Chem Ltd. is a specialty chemicals manufacturer dealing with a variety of products including structure directing agents, phase transfer catalysts, pharmaceutical and agrochemical intermediates, and other specialty chemicals.
It is the largest and only commercial manufacturer of structure-directing agents for zeolites in India (second globally).
Tatva Chintan’s products, totalling over 154, have wide applications across automotive, petroleum, agrochemicals, dyes and pigments, paints and coatings, pharmaceutical and personal care.
It exports to over 25 countries, which contributed over 70% of total revenues from operations for FY21.
Revenues have grown at a compound annual growth rate of 21.7% over last two years, while the Ebitda margins have improved by 600 basis points to 23% over the same period.
Click on the attachment to read the full IPO report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.